Aline Renneville
A5059057760- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Eosinophilic Disorders and Syndromes
- Renal and related cancers
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Blood disorders and treatments
- Histone Deacetylase Inhibitors Research
- Ubiquitin and proteasome pathways
- HIV/AIDS drug development and treatment
- Sarcoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Galectins and Cancer Biology
- Retinoids in leukemia and cellular processes
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
Institut Gustave Roussy
2013-2025
Inserm
2011-2024
Centre National de la Recherche Scientifique
2013-2024
Université Paris-Saclay
2021-2024
Centre Hospitalier Universitaire de Lille
2013-2022
Hôpital Claude Huriez
2008-2022
Institut de Biologie de Lille
2008-2021
Dana-Farber Cancer Institute
2021
Broad Institute
2018-2021
Université Lille Nord de France
2010-2020
Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present data obtained from 2345 leukemia patients. Genomic breakpoints within MLL involved translocation partner genes (TPGs) were determined 11 novel TPGs identified. Thus, a total 135 different have been identified so far, which 94 now characterized at molecular level. In all, 35 out these occur recurrently, but only 9 specific fusions account for...
Purpose Several prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutations—including ASXL1—have associated with poor prognosis univariable analyses. We developed and validated score overall survival (OS) based on mutational status standard clinical variables. Patients Methods genotyped ASXL1 up to 18 other genes including epigenetic (TET2, EZH2, IDH1, IDH2, DNMT3A), splicing (SF3B1, SRSF2, ZRSF2, U2AF1), transcription...
Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize chromosomal rearrangement individual leukemia patients. present data molecular characterization 1590 MLL-rearranged biopsy samples obtained from The precise localization genomic breakpoints within involved translocation partner genes (TPGs) were determined...
Purpose Risk stratification in acute myeloid leukemia (AML) is currently based on pretreatment characteristics. It remains to be established whether relapse risk can better predicted through assessment of minimal residual disease (MRD). One proposed marker the Wilms tumor gene WT1, which overexpressed most patients with AML, thus providing a putative target for immunotherapy, although absence standardized assay, its utility MRD monitoring controversial. Patients and Methods Nine published...
Thalidomide-targeted degradation Thalidomide and its analogs improve the survival of patients with multiple myeloma other blood cancers. Previous work showed that drugs bind to E3 ubiquitin ligase Cereblon, which then targets for two specific zinc finger (ZF) transcription factors a role in cancer development. Sievers et al. found more ZF proteins than anticipated are destabilized by thalidomide analogs. A proof-of-concept experiment revealed chemical modifications can lead selective...
Purpose This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed question whether NPM1m MRD may be used as a predictive factor allogeneic stem cell transplantation (ASCT) benefit. Patients Methods Among 229 who were treated Acute Leukemia French Association 0702 (ALFA-0702) trial, evaluation was available 152 first remission. nonfavorable AML...
Recently, whole-genome sequencing in acute myeloid leukemia (AML) identified recurrent isocitrate dehydrogenase enzyme isoform (IDH1) mutations (IDH1m), previously reported to be involved gliomas as well IDH2 (IDH2m). The prognosis of both IDH1m and IDH2m AML remains unclear.The prevalence the prognostic impact R132 IDH1 R172 were evaluated a cohort 520 adults with homogeneously treated French Acute Leukemia Association (ALFA) -9801 -9802 trials.The was 9.6% 3.0%, respectively, mostly...
Purpose To determine whether minimal residual disease (MRD) measured by Wilms' tumor gene 1 (WT1) expression is a prognostic marker in pediatric acute myeloid leukemia (AML), we quantified WT1 transcript real-time quantitative-polymerase chain reaction 92 AML at diagnosis and during follow-up. Patients Methods (median age, 6 years; cytogenetics, favorable 27%, intermediate 59%, poor 13%) were treated between 1995 2002 enrolled Leucémie aiguë Myéloblastique Enfant (LAME) 89/91, LAME 99 pilot...
Purpose Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high levels of 2-hydroxyglutarate (2-HG). We investigated whether, in acute myeloid leukemia (AML), serum 2-HG would predict the presence IDH1/2 mutations at diagnosis provide a marker minimal residual disease (MRD). Patients Methods Serum samples from 82 patients de novo AML (IDH1/2 mutated, n = 53) 68 without were analyzed for total its ratio D to L stereoisomers by mass spectrometry. measured molecular markers MRD (WT1 NPM1)...